{"id":"NCT03583333","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)","officialTitle":"A Multi-national Phase 3, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-18","primaryCompletion":"2022-07-12","completion":"2022-07-12","firstPosted":"2018-07-11","resultsPosted":"2023-06-28","lastUpdate":"2025-01-29"},"enrollment":274,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hospital-Acquired Bacterial Pneumonia","Ventilator-Associated Bacterial Pneumonia"],"interventions":[{"type":"DRUG","name":"IMI/REL FDC","otherNames":["MK-7655A"]},{"type":"DRUG","name":"PIP/TAZ FDC","otherNames":[]},{"type":"DRUG","name":"Linezolid","otherNames":[]}],"arms":[{"label":"IMI/REL FDC","type":"EXPERIMENTAL"},{"label":"PIP/TAZ FDC","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the efficacy and safety of a FDC of imipenem/cilastatin (IMI) and relebactam (REL) \\[IMI/REL, MK-7655A\\] compared to piperacillin/tazobactam (PIP/TAZ) in the treatment of adults diagnosed with Hospital-Acquired Bacterial Pneumonia (HABP) or Ventilator-Associated Bacterial Pneumonia (VABP). The primary hypothesis is that IMI/REL is non-inferior to PIP/TAZ as measured by the incidence rate of all-cause mortality through Day 28 post-randomization.","primaryOutcome":{"measure":"Percentage of Participants With All-cause Mortality Through Day 28 in the Modified Intent to Treat (MITT) Population","timeFrame":"Up to approximately 28 days","effectByArm":[{"arm":"IMI/REL FDC","deltaMin":11.2,"sd":null},{"arm":"PIP/TAZ FDC","deltaMin":5.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.024"},{"comp":"OG000 vs OG001","p":"0.938"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":16},"locations":{"siteCount":68,"countries":["Brazil","China","France","Mexico","Philippines","Romania","Russia","Ukraine"]},"refs":{"pmids":["39674398"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":134},"commonTop":["Diarrhoea","Anaemia","Hepatic function abnormal","Hypokalaemia","Hyponatraemia"]}}